Bioactivity:

PRLX-93936 is an analog of erastin that has antitumor activity. It inhibits the hypoxia-inducible factor 1 (HIF-1) signaling pathway under hypoxic conditions (IC50 = 0.09 _M in a cell-based reporter assay). PRLX-93936 (1 _M) also inhibits hypoxia-induced increases in HIF-1_ expression in ME-180 cervical cancer cells. It inhibits the growth of HT-1080 fibrosarcoma, OVCAR-5 ovarian cancer, BJELR tumorigenic primary fibroblast, and PANC-1 pancreatic cancer cells with IC50 values of less than 100 nM. PRLX-93936 inhibits tumor growth in PANC-1 and HT-1080 xenograft models when administered at a dose of 50 mg/kg and induces tumor regression when administered at a dose of 100 mg/kg.

CAS nr:

903499-49-0

Purity:

98%

Molecular Weight:

364,449

SMILES:

CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O

Formula:

C21H24N4O2

Pathway:

Target: